Get the Stockscreener App
7.68
3.43%
0.255
Evolus Inc stock is traded at $7.68, with a volume of 1.34M.
It is up +3.43% in the last 24 hours and down -19.75% over the past month.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
See More
Previous Close:
$7.425
Open:
$7.51
24h Volume:
1.34M
Relative Volume:
0.99
Market Cap:
$496.78M
Revenue:
$202.09M
Net Income/Loss:
$-61.69M
P/E Ratio:
-7.1111
EPS:
-1.08
Net Cash Flow:
$-35.64M
1W Performance:
+14.12%
1M Performance:
-19.75%
6M Performance:
-45.10%
1Y Performance:
-50.39%
1-Day Range:
$7.46
$7.91
1-Week Range:
$6.55
$7.91
52-Week Range:
$5.71
$17.82
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
7.68 | 432.75M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Downgrade | Needham | Buy → Hold |
| Apr-17-25 | Initiated | BTIG Research | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Brady Stewart Bought 59% More Shares In Evolus - simplywall.st
Evolus Submits Evolysse Sculpt for FDA Approval, Expanding HA Dermal Filler Portfolio - Dermatology Times
Evolus submits Evolysse premarket approval application to FDA - TipRanks
Evolus submits final FDA application for mid-face volume filler - Investing.com
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse?? Sculpt Injectable Hyaluronic Acid Gel Product - MarketScreener
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product - Business Wire
Evolus plunges after Q2 miss, guidance cut; Needham downgrades - MSN
Director’s Bold Move: Major Stock Purchase Signals Confidence in Evolus - TipRanks
Evolus Sees Aesthetic Market Slowing After Q2 Miss - Orange County Business Journal
Is Evolus Inc. stock technically oversold2025 Trading Volume Trends & Low Drawdown Momentum Trade Ideas - thegnnews.com
Is Evolus Inc. Forming a Consolidation BaseJuly 2025 Recap & Trade Opportunity Analysis - metal.it
Live Scanner Shows Breakout on Evolus Inc.Jobs Report & Verified High Yield Trade Plans - 선데이타임즈
Evolus announces commercial launch of Evolysse - MSN
Midday Stock Roundup: ICU Medical Soars, Willdan Group Down - Orange County Business Journal
Is This the Dip to Buy in Evolus Inc.July 2025 Pullbacks & Capital Protection Trade Alerts - metal.it
Resistance Break Could Fuel Evolus Inc. Rally2025 Risk Factors & High Accuracy Swing Entry Alerts - classian.co.kr
Evolus Q2 2025: Unpacking Contradictions in Toxin Demand, Evolysse Launch, and Consumer Sentiment - AInvest
Evolus, Inc. shares rise 11.53% intraday after reporting inducement grants to new employees. - AInvest
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
How liquid is Evolus Inc. stockNext Day Profit Stock Signals - newsyoung.net
Analysts Just Slashed Their Evolus, Inc. (NASDAQ:EOLS) EPS Numbers - simplywall.st
Evolus (EOLS): Navigating Earnings Revisions and Long-Term Potential in the Aesthetic Medicine Sector - AInvest
Evolus, Inc. Sees Significant Downgrades to Consensus EPS Estimates - AInvest
The Consensus EPS Estimates For Evolus, Inc. (NASDAQ:EOLS) Just Fell Dramatically - Yahoo Finance
The recent earnings and revenue miss by Evolus EOLS -2.80% (EOLS) has sent shockwaves through the aesthetic medicine sector, with sharp downward revisions in analyst expectations raising questions about the company's long-term viability. Q2 2025 res - AInvest
When Will Evolus, Inc. (NASDAQ:EOLS) Turn A Profit? - 富途牛牛
Evolus, Inc. Faces Financial Uncertainty Due to Consumer Spending Risks and Economic Volatility - AInvest
Evolus Receives Buy Rating from Leerink Partners - AInvest
Evolus, Inc. Advances Safety Study of NUCEIVA for Glabellar Lines - TipRanks
A Quick Look at Today's Ratings for Evolus(EOLS.US), With a Forecast Between $18 to $20 - 富途牛牛
Evolus, Inc. (NASDAQ:EOLS) Q2 2025 Earnings Call Transcript - Insider Monkey
Evolus, Inc. Faces Financial Instability Amid Economic Uncertainty and Consumer Spending Risks - TipRanks
Evolus Q2 Earnings: Mixed Sentiments and Strategic Goals for Growth - AInvest
Evolus Maintains Buy Rating Amid Market Challenges Despite Reset in 2025 Revenue Guidance - AInvest
Evolus, Inc. (EOLS) Reports Q2 Loss, Lags Revenue Estimates - MSN
Evolus, Inc. Earnings Call: Mixed Sentiments and Strategic Goals - TipRanks
Evolus Appoints New Principal Financial Officer - MSN
Evolus 2025 Q2 Earnings Misses Targets, Net Loss Widens by 51% - AInvest
Evolus stock down on Q2 miss; Needham downgrades (EOLS:NASDAQ) - Seeking Alpha
Evolus, Inc. shares fall 30.53% intraday after disappointing Q2 earnings and lowered 2025 sales target. - AInvest
Evolus Sees Steady Gains And Eyes Profit Next Year - Finimize
Evolus Reports Q2 Revenue of $69.4mln, Misses Estimates by 15.4%, Lowers Full-Year Guidance - AInvest
Evolus stock price target lowered to $20 by H.C. Wainwright on market headwinds - Investing.com Canada
Evolus price target lowered to $18 from $21 at BTIG - TipRanks
Evolus: HC Wainwright Maintains Buy, PT Down to $20 from $27 - AInvest
Evolus stock price target lowered to $18 at BTIG on Q2 revenue miss By Investing.com - Investing.com South Africa
Evolus stock price target lowered to $18 at BTIG on Q2 revenue miss - Investing.com India
Evolus Stock Plunges 25.14% on Disappointing Earnings - AInvest
Evolus Q2 2025 slides: Filler launch drives market expansion despite earnings miss - Investing.com Nigeria
Evolus, Inc. Reports Q2 2025 Financial Results - TipRanks
Evolus outlines $700M 2028 revenue target and cost realignment amid market softness - MSN
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Evolus Inc Stock (EOLS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MOATAZEDI DAVID | See Remarks |
Jun 13 '25 |
Sale |
10.05 |
111,323 |
1,119,141 |
381,509 |
| MOATAZEDI DAVID | See Remarks |
Jun 16 '25 |
Sale |
9.89 |
16,582 |
164,054 |
364,927 |
2.37%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):